HER-2/neu expression in lesions of uterine cervix: Is it reliable and consistent?

Gupta, Nidhi; Singh, Sunita; Marwah, Nisha; Kumar, Sanjay; Chabra, Sonia; Sen, Rajeev

doi:10.4103/0377-4929.56127

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Out of 62 studies reporting on HER2 positivity prevalence by IHC, 26 (41.9%) used the positivity definition and grading criteria consistent with ASCO/CAP 2007, 2013, or 2018 guidelines and have been classified as ASCO/CAP compliant, while the remaining 36 (58,1%) studies were classified as ASCO/CAP non-compliant ( Fig 3 and Table 1 ). Among ASCO/CAP compliant studies, five used the 30% positivity cut-off point (ASCO/CAP 2007) [ 25 , 38 , 40 , 48 , 52 ], and 19 studies the 10% cut-off point (ASCO/CAP 2013 or 2018) [ 30 , 36 , 37 , 39 , 41 , 42 , 44 , 45 , 47 , 49 , 51 , 55 , 56 , 58 , 60 , 65 , 67 , 70 – 72 ]. Nine out of 11 studies that used ISH followed ASCO/CAP compliant or slightly more stringent positivity criteria ( S6 File ).…”

Section: Resultsmentioning

confidence: 99%

“…Overall, the estimated pooled prevalence of HER2 overexpression was 17.0% (95% confidence interval [95%CI]: 11.7% to 23.0%), I 2 = 96% ( S9 File ). If only studies that used an ASCO/CAP compliant IHC method (26 studies, N = 2135) were included, under the random-effects model the estimated pooled prevalence of HER2 overexpression was 5.7%, (CI 95%: 1.5% to 11.7%), I 2 = 87% ( Fig 3 ) [ 25 , 26 , 30 , 36 – 42 , 44 , 45 , 47 – 49 , 51 , 52 , 55 , 56 , 58 , 60 , 65 , 67 , 70 – 72 ]. In the subset of studies considered ASCO/CAP non-compliant (36 studies, N = 2 941), the estimated pooled prevalence of HER2 overexpression was 27.0%, (IC 95%: 19.8% to 34.8%), I 2 = 96% ( Fig 3 ).…”

Section: Resultsmentioning

confidence: 99%

“…As significant heterogeneity in the ASCO/CAP compliant subgroup persisted, we conducted influence and moderator analyses. Although two studies have been identified as outliers, they were not considered influential cases since their removal neither significantly shifted the summary proportion nor markedly reduced the heterogeneity ( S10 File ) [ 45 , 55 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis

Itkin

García²,

Straminsky

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

The reported rates of HER2 positivity in cervical cancer (CC) range from 0% to 87%. The importance of HER2 as an actionable target in CC would depend on HER2 positivity prevalence. Our aim was to provide precise estimates of HER2 overexpression and amplification in CC, globally and by relevant subgroups. We conducted a PRISMA compliant meta-analytic systematic review. We searched Medline, EMBASE, Cochrane database, and grey literature for articles reporting the proportion of HER2 positivity in CC. Studies assessing HER2 status by immunohistochemistry or in situ hybridization in invasive disease were eligible. We performed descriptive analyses of all 65 included studies. Out of these, we selected 26 studies that used standardized American Society of Clinical Oncology / College of American Pathologists (ASCO/CAP) Guidelines compliant methodology. We conducted several meta-analyses of proportions to estimate the pooled prevalence of HER2 positivity and subgroup analyses using geographic region, histology, tumor stage, primary antibody brand, study size, and publication year as moderators. The estimated pooled prevalence of HER2 overexpression was 5.7% (CI 95%: 1.5% to 11.7%) I2 = 87% in ASCO/CAP compliant studies and 27.0%, (CI 95%: 19.9% to 34.8%) I2 = 96% in ASCO/CAP non-compliant ones, p < 0.001. The estimated pooled prevalence of HER2 amplification was 1.2% (CI 95%: 0.0% to 5.8%) I2 = 0% and 24.9% (CI 95%: 12.6% to 39.6%) I2 = 86%, respectively, p = 0.004. No other factor was significantly associated with HER2 positivity rates. Our results suggest that a small, but still meaningful proportion of CC is expected to be HER2-positive. High heterogeneity was the main limitation of the study. Variations in previously reported HER2 positivity rates are mainly related to methodological issues.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis

Itkin

García²,

Straminsky

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

show abstract

Her-2 neu expression in cervical intraepithelial neoplasia and carcinoma of cervix

Chaudhary¹,

Pant²,

Khandelwal³

et al. 2020

IJPO

View full text Add to dashboard Cite

Currently radiotherapy, cisplatin based chemo-radiation and surgery are used in combination for treating cervical cancer according to stage of the tumor. Patients with advanced disease stage have limited treatment options with median overall survival of less than one year. Therefore, there is increasing interest in using targeted therapy as a treatment modality. There are controversial views of various authors regarding role of Her-2 neu targeted therapy in cervical carcinoma. The present study was conducted to evaluate the expression of Her-2 neu in Pre-malignant and Malignant lesions of cervix and attempt its correlation with histological type, grade and stage of the tumor. A cross-sectional observational study was conducted from January 2017 to January 2018 including a total of 55 patients with either pre-malignant and malignant lesions of cervix. Rabbit monoclonal Antibody to Her2/ErBb2 from BioGenex was used for staining. Intensity of Her-2 neu expression was graded according to the 2014 ASCO/CAP guidelines for Her-2 reporting. There was higher expression of Her-2 neu expression in HSIL then LSIL. There was significant correlation between Her-2 neu expression and histological types of malignant lesions. There was no significant correlation between Her-2 neu expression and pre-malignant lesions, stage of cervical carcinoma and grades of squamous cell carcinoma. Her-2 neu has a role in higher grade of cervical lesions but studies with larger cohorts are needed to comment upon its definite role in targeted therapy.

show abstract

Role of HER2/neu expression in premalignant and malignant lesions of uterine cervix

Vijayalakshmi¹,

N²,

Rani³

2022

IJPO

View full text Add to dashboard Cite

Many research studies on various biomarkers were done, in analysing the prognosis and in evaluation of therapeutic target strategies which improves the survival rate in carcinoma of cervix. Of these, one of the important biomarker is HER-2/neu. To correlate histomorphology of cervical lesions, various clinicopathological parameters with HER-2/neu. The present study conducted during the period from June 2017 to May 2019 in department of Pathology, Madurai Medical College, Madurai. 200 cases were selected for study. Among those, 50 cases were selected for immunohistochemical studies with HER 2. Out of 50 cases included, higher HER 2 positivity was observed in HSIL as compared to LSIL. In malignant lesions, positive immunostaining was observed in 71.05% cases. Positivity was seen in 70% of cases of squamous cell carcinoma and 75% of cases of adenocarcinoma cases. Progression of clinical spectrum of the lesion is associated with overexpression if HER 2, suggesting HER 2 can be considered as one of poor prognostic factor. Malignant lesions expressed greater positivity than premalignant lesions. Also, overexpression of HER 2 is associated with progressing grade and advanced stage of cervical carcinoma.

show abstract

HER-2/neu expression in lesions of uterine cervix: Is it reliable and consistent?

Cited by 7 publications

References 0 publications

Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis

Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis

Her-2 neu expression in cervical intraepithelial neoplasia and carcinoma of cervix

Role of HER2/neu expression in premalignant and malignant lesions of uterine cervix

Contact Info

Product

Resources

About